{"title": "PDF", "author": "PDF", "url": "https://www.umt.edu/pharmacy-practice/cpe/covid-19-ce-2022-final.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "COVID -19 Outpatient Treatment with Focus on Antivirals Rose Macklin, Pharm.D . BCPS Partners in Home Care, UM College of Health Disclosure Statement I have no relevant financial relationship(s) with ineligible companies to disclose. I am not an expert on COVID -19 caused by SARS CoV -2.Objectives Review pathology of SARS -CoV-2 infection Outline general approach to outpatient treatment Discuss mechanism of action, key study findings, and usage overview of three antivirals: Nirmatrelvir /Ritonavir Remdesivir Molnupiravir Discuss efficacy and place in therapy for Sotrovimab Given a case scenario, choose best outpatient treatment option Learn about resources to obtain up -to-date COVID -19 treatment informationIntroduction Novel coronavirus (SARS -CoV2) Dec 2019 -First cases of pneumonia identified in Wuhan, China Early Jan 2020 -virus genetic sequence identified and shared globally Feb 2020 -first EUA test kits produced and remdesivir trials begin March 11, 2020 -WHO declares pandemic Oct 2020 -First IV antiviral approved Dec 2020 -First vaccine available Dec 2021 -First oral antiviral approved Many features to lead to a severe pandemic Emerging pathogen (virus), rapidly spreads (person -to-person), not effected by climate, severe course, ability to mutate Global stats as of 3/1/22* Cases > 438 million Deaths > 5.96 million US deaths > 951,315 *Stats from Johns Hopkins Coronavirus Resource Center 3/1/22Clinical Spectrum Asymptomatic 30% Of those with symptoms Mild Illness 81% Fever, cough, sore throat, HA, malaise, muscle pain, N/V/D, loss of taste or smell Severe 14% Dyspnea RR> hypoxia lung infiltrates Critical 5% respiratory failure, septic shock, multiple organ dysfunction Fatality rate 1.6 -2.3% all deaths were in critical classification Recovery 2-3 weeks for mild course 2-3+ months for more severe disease Unclear course for those with persistent symptomsAfter the initial exposure, patients typically develop symptoms within 5 -6 days (incubation period). Muge Cevik et al. BMJ 2020;371:bmj.m3862 \u00a92020 by British Medical Journal Publishing Group(1) The virus binds to ACE 2 as the host target cell receptor in synergy with the host's transmembrane serine protease 2 (cell surface protein), which is principally expressed in the airway epithelial cells and vascular endothelial cells . Muge Cevik et British Medical Journal Publishing GroupRisk Factors for Severe Symptoms/Poorer Outcomes Older age Cancer Chronic kidney disease Chronic liver disease Chronic lung disease Asthma, uncontrolled COPD, Cystic fibrosis Dementia Diabetes (Type 1 or 2) Down syndrome Heart disease Heart failure, CAD, cardiomyopathy Immunocompromised HIV, genetic states, chronic oral steroid or immunosuppressant useMental health Depression, schizophrenia Obesity Pregnancy Sickle cell disease or thalassemia Smoking Solid organ or stem cell transplants Stroke Substance use disorder Tuberculosis Racial & ethnic minorities Socioeconomic factorsRisk for COVID -19 Infection, Hospitalization, and Death By Age Group Rate compared Hospitalization, & Death By Race/Ethnicity Race and ethnicity are risk markers for other underlying conditions that impact health: socioeconomic status, access to HC, & exposure to virus. Rate ratios compared to White, Non - Hispanic personsAmerican Indian or Alaska Native AsianBlack or African AmericanHispanic 5 yo-2 doses 3 weeks apart. Moderna 18 yo-2 doses 4 weeks apart. Adults. Efficacy rates were 90 -95% after two doses in preventing symptomatic COVID -19 An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years. Additional dose if high risk of suboptimal immune response to two -dose series at least 28 days later Adenoviral vector vaccine Janssen/J&J/Merck 18 yo-1 dose Standard storage, second 67-85% prevention of moderate -critical COVID -19 Boosters: J&J (2 months), Pfizer and Moderna (5 months). Local and systemic ADRs common, especially after 2nddose Rare: -COV) Post-exposure prophylaxis (PEP) for those who have a history of exposure to individuals with SARS -CoV-2 infection and who are at high risk of progression to serious disease if they acquire the infection. Treatment of non -hospitalized patients with mild to moderate COVID -19 who are at high risk for clinical progression. Limited data currently Early results suggest possible benefit in outpatient groups not requiring O2 No benefit/worse outcomes seen in hospitalized patient populations Administer ASAP after (+) test and within 10 days of symptom onset SE: N/V/D, dizziness, HA, pruritus, infusion rxn, anaphylaxis Need to delay mRNA vaccine for at least (Evusheld ) EUA Indication: Pre-exposure prophylaxis for adults and adolescents (aged 12 years and weighing 40 kg) who do not have SARS -CoV-2 infection, who have not been recently exposed to an individual with SARS -CoV-2 infection, AND who: Are moderately to severely immunocompromised and may have an inadequate immune response to COVID -19 vaccination Active cancer treatment, organ or bone marrow transplant, untreated/advanced HIV, immunodeficiencies Active treatment with high -dose corticosteroids (i.e., 20 mg/day prednisone for 2 weeks), alkylating agents, antimetabolites, transplant - related immunosuppressive drugs, cancer chemotherapy, tumor -necrosis blockers, etc. Are not able to be fully vaccinated due to history of severe adverse reactions to a COVID -19 vaccine or any of its components. Not for unvaccinated individuals just by choice.Tixagevimab + cilgavimab (Evusheld ) MOA: Dual mAB therapy with alternation to prolong circulation for up to 6 months. Cilgavimab retains activity against Omicron VOC PROVENT trial -19 infection 77% (0.2% mAB vs 1% placebo) at median 83 days, p<0.001 ADRs: 35% mild -moderate, 1% serious ADR, comparable to placebo Dosing Each package of Evusheld includes a vial of tixagevimab and a vial of cilgavimab , each containing a single 150 mg/1.5 mL dose (100 mg/mL concentration per vial). Given as 2 consecutive IM injections. Dose now 300 mg of each due to some resistance by Omicron VOC. If only received 150 mg dose then repeat dose ASAP. Give in gluteal muscle. Can be redosed every 6 months if meet criteria If a person has received a COVID -19 vaccine, tixagevimab plus cilgavimab should be administered 2 weeks after vaccination.Prioritization for Outpatient Treatment Tier1 Immunocompromised individuals not expected to mount an adequate immune response to COVID -19 vaccination or infection due to their underlying conditions, regardless of vaccine status Unvaccinated individuals at the highest risk of severe disease (anyone aged 75 years or anyone aged 65 years with additional risk factors) Tier 2 Unvaccinated individuals at risk of severe disease not included in Tier 1 (anyone aged 65 years or anyone aged <65 years with clinical risk factors) Tier 3 Vaccinated individuals at high risk of severe disease (anyone aged 75 years or anyone aged 65 years with clinical risk factors) * Tier 4 Vaccinated individuals at risk of severe disease (anyone aged 65 years or anyone aged <65 with clinical risk factors) * Note: Vaccinated individuals who have not received a COVID -19 vaccine booster dose are likely at higher risk for severe disease; patients in this situation within this tier should be prioritized for treatment.NIH COVID -19 Treatment Guidelines on Therapies for High-Risk, Non -Hospitalized Patients With Mild to Moderate COVID -19 Preferred therapies in order of preference: Nirmatrelvir 300 mg plus ritonavir 100 mg (Paxlovid) orally twice daily for 5 days Sotrovimab ( Xevudy ) 500 mg, administered as a single intravenous (IV) infusion Remdesivir (Veklury ) 200 mg IV on Day 1, followed by remdesivir 100 mg IV on Days 2 and 3 Alternative therapies: Molnupiravir 800 mg orally twice daily for 5 days Bebtelovimab 175 mg IV injection NIH recommends against Nitazoxanide , Hydroxychloroquine or Chloroquine and/or Azithromycin, Lopinavir /Ritonavir and other HIV protease inhibitors. Insufficient evidence either for or against ivermectinCase 1 MR is a 56 yoman presenting to walk -in clinic with 3 -day history of worsening congestion, persistent cough, and headache. His wife tested positive for COVID 5 days ago. Pt has Type 2 diabetes, hypertension, hyperlipidemia and obesity (BMI 31.2). A rapid test is positive for SARS CoV-2. Pt is unvaccinated with no history prior COVID infection. VS: Temp 100.5, RR 24, HR 90, BP 140/72, O2 room 30 units QHS, mg 100 mg 10 mg qpm, and aspirin 81 mg QD Which Tier does he fall into for outpatient treatment of COVID -19? What treatment options does he potentially qualify for, if ; 12/21 EUA for outpt treatment of mild to moderate COVID -19 in adults and children >12 yrs& weigh at least 40 kg who are at high risk for severe COVID -19 illness. Patients with mild to moderate COVID -19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID -19 may also receive drug. Cuts risk of hospitalization or death by 89% compared to placebo in non - hospitalized high -risk adults with COVID -19. Not approved for: Initiation of treatment in patients requiring hospitalization due to severe or critical COVID -19 Use as pre -exposure or post -exposure prophylaxis Use for longer than 5 consecutive daysProtease Inhibitor Action Kaiming Tao, et al. SARS -CoV-2 Antiviral therapy. ASM Journals, Clinical Microbiology Reviews. Vol 34, No. 4, published 7/28/21. accessed at https://journals.asm.org/doi/full/10.1128/CMR.00109 -21Paxlovid EPIC -HR trial Phase 2/3 in 2000+ participants Randomized, placebo -controlled, double -blinded Inclusion: Covid +, mild -moderate symptoms <5 days, 12 yrsor older and weigh 40 kg, at least one risk factor for progression Exclusion: Hospitalized or requiring oxygen therapy Study excluded children, pregnant women, individuals with GRF<45 ml/min/1.73m2, active liver disease, & pts on DI meds with Paxlovid . Standard of care treatment allowed, but the primary analysis population was limited to subjects who did not receive COVID -19 mAB therapy (2,246 pts) 98% Delta variant Paxlovid 3 tabs q12 hrsx 5 days or placebo Primary outcomes: hospitalization or death from COVID -19 at 28 -HR Results Endpoints Paxlovid N=1,039Placebo N=1,046 COVID -19related hospitalization or death from any cause through Day 28, n (%)8 (0.08%) 66 (6.3%) Reduction relative to placebo (95%, CI), % -5.62 (-7.21 to -4.03) All-cause mortality through Day 28, % 0 12 (1.1%) 88% RRR for COVID -19 hospitalization or death for any cause Treatment effects were generally consistent across subgroups If treat within 3 days, better at reducing hospitalization rates <3 days of symptoms: Paxlovid 0.8% Discontinuation 2.1% 4.1%Paxlovid Dosing Oral antiviral pill taken twice a daily x 5 days, start ASAP but within 5 days of symptom onset. Nirmatrelvir 150 mg 2 tabs q12hrs x 5 days + Ritonavir 100 mg 1 tab q12hrs x 5 days With or without food eGFR >30-60 ml/min: 1 tab Nirmatrelvir BID (RPH removes tabs from blister packet) Avoid in severe renal ( eGFR < 30 ml/min) or liver impairment (Child - Pugh Class C) No data if pregnant/breast -feeding or children < 12 yrs Paxlovid: Drug Interactions ! Paxlovid inhibits CYP3A and is metabolized by CYP3A Contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or triazolam , oral midazolam Contraindicated with that CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. Paxlovid cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently Paxlovid: Drug Interactions Healthcare providers should: Inform patients of drug interactions Obtain complete medication list (RX, OTC, herbal) Check for clinically significant drug interactions: Section 7.3 of EUA Fact Sheet: druginteractions.org/ Based on interactions, decide if: Paxlovid use is appropriate vs an alternative authorized treatment If appropriate, whether patient should hold, change, or dose -reduce other medications while taking drug, of if additional monitoring is neededSotrovimab Human monoclonal antibody neutralizes SARS -CoV-2 & other sarbecoviruses; targets a highly conserved epitope EUA for mild -to-moderate COVID -19 in adults and pediatric patients (12 years and >40 kg) who are at high risk for progression to severe COVID -19, including hospitalization or death. Give ASAP but within 10 days of symptom onset. Not approved for: Hospitalized due to COVID -19, Require oxygen therapy due to COVID -19, Require an increase in baseline oxygen flow rate due to COVID -19. Sotrovimab COMET -ICE Trial Multicenter (37 sites in 4 countries), double -blind, phase 3 trial Inclusion criteria: Non -hospitalized patients with symptomatic Covid -19 (5 days after the onset of symptoms) and at least one risk factor for disease progression received sotrovimab 500 mg IV x 1 or placebo NS. Exclusion criteria: severe COVID -19 (dyspnea at rest, O2 sats <94%, O2 use) Pts received local standard of care. Interim analysis planned Primary outcome: hospitalization (>24 hours) for any cause or death within 29 days. Secondary outcome % patients with an ED visit, hospitalization, or death % patients with disease progression needing O2 Safety evaluation: Adverse events, including infusion reactions. Immunogenicity testing for antidrug antibodies and antibody -dependent enhancement All hospitalizations counted as serious AECOMET -ICE Interim Results 583 patients efficacy results; 868 pts in adverse event results Similar baseline characteristics, 63% Latino/Hispanic Efficacy: The relative reduction in hospitalization or death was 85% for Sotrovimab vs placebo. Gupta A, et al. Early treatment of COVID -19 with SARS -CoV-2 neutralizing Primary Outcome N (%) ICU admit Death3 (1%) 0 021 (7%) 5 1 Adverse Events N (%) Infusion Reaction (%)73 (17%) 1%85 (19%) 1% Serious & Side Effects Dilute 500 mg/8 ml in 50 or 100 ml NS or D5W bag x 1 dose No dose adjustment for renal or hepatic impairment. Administer sotrovimab by IV infusion over 30 minutes. Flush well. Monitor patients during infusion and observe patients for at least 1 hour after infusion is complete. Anaphylaxis kit available & EMS available. COMET -TAIL trial: IM non -inferior to IV route Pruritus, skin rash, diarrhea, chills, infusion related reactions & anaphylaxis. Not studied during pregnancy. Pregnancy or breast -feeding should not be a reason to withhold if indicated and ptconsents. COVID vaccine: vaccinate 90 days after mAB . Wait 2 weeks after vaccination to give alanine analog into growing RNA chains, inhibiting RNA - dependent RNA polymerase and terminating growing viral chains prematurely. FDA approved drug to treat COVID -19 in patients 12 yrs& weigh at least 40 kg, who are: Hospitalized, Not hospitalized and have mild -to-moderate COVID -19 with high risk for progression to severe COVID -19 Recommended for hospitalized patients requiring supplemental O2: Remdesivir alone if minimal oxygen needed Remdesivir + Dexamethasone if requiring increasing amounts of O2 Not recommend if require IMV or ECMO (lack of benefit) EUA use Treatment of COVID -19 in pediatric patients weighing 3.5 kg to less than 40 kg or pediatric patients less than 12 years of age weighing at least 3.5 kgMalin, JJ, et al. Remdesivir against COVID -19 and other viral diseases. ASM Journals/Clinical Microbiology Reviews; Vol 34, No. 1, 10/2020 accessed 12/15/2021.Remdesivir Dosing & ADRs Dosing: 200mg IV x 1 day, then 100mg daily for days 2 -5 or until discharge Start within 72 hrsof positive test May extend up to 10 days in certain patients SE: nausea (7%), if renal (not recommended GFR 30) Discontinue if ALT>10 times ULN or if elevated ALT and s/s of liver inflammation ACTT -1 Study: Remdesivir for of COVID -19 -blind, randomized, placebo -controlled trial in 60 sites Inclusion: Adults hospitalized with COVID -19 & lower respiratory tract infection Stratified based on respiratory severity; 8 categories Received supportive care & other treatments for COVID based on hospital protocols Remdesivir 200 mg Day 1, then 100 mg QD or Placebo for up to 10 days or hospital discharge Primary outcome: Time to recovery by Day 29 Secondary outcome: clinical status at Day 15 with 8 categories, time to improvement, hospitalization length, & mortality at 14 & 28 days.ACTT -1 Trial Baseline Demographics: 1062 patients randomized: 541 to Remdesivir , 521 to placebo Mean age 58 yrs, 64% male, 53% White, 23% Hispanic, 21% AA, 12% Asian Median time from symptom onset to randomization -9 days Co-exising conditions: None (19%), were on IMV/ECMO than Remdesivir (26.8%). Results: Largest difference in groups (benefit) in time to recovery and risk of death was seen in Group 5: hospitalized & requiring low -flow oxygen Benefit was greater if given early in the disease course The initial length of hospital stay was shorter in the remdesivir group than in the placebo group (median, 12 days vs. 17 days) 5% of patients in the remdesivir group were readmitted compared with 3% in the Outcomes: ACTT -1 Trial Remdesivir N541 Placebo N521 No. of Recoveries 399 352 Median Time to Recovery -days 10 (9 -11) 15 (13 -18) Rate Ratio (95% CI) 1.29 (1.12 -1.49) p<0.001 Mortality through Day 14 Hazard Ratio (95% CI) 0.55 (0.36 -0.83) No. of Deaths by day 15 35 61 Kaplan -Meier Est of D15 mortality % 95% CI6.7 (4.8-9.2)11.9 (9.4-15.0) Hazard ratio (95% CI) 0.73 (0.52 -1.03) No. of Deaths by Day 29 59 77 Kaplan -Meier Est of D29 mortality % 95% CI11.4 (9.0-14.5)15.2 (12.3 -18.6) Serious Adverse Events % 24.6 31.6WHO Solidarity Therapeutics Trial Mortality trials for 4 antiviral drugs: remdesivir, hydroxychloroquine, lopinavir & interferon beta -1a in hospitalized patients with COVID -19. Randomize to one of four meds as available at each site or local standard of care Rate ratios for death stratified by age and status regarding mechanical ventilation at trial entry. 405 hospitals in 30 countries: trial drug. Midway adherence to treatment 95% WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid -19-Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384:497 -511. Accessed at: https://www.nejm.org/doi/full/10.1056/nejmoa2023184 on 12/17/21.Solidarity Trial Results In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan -Meier 28 -day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50), Death in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P=0.23), Death in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P=0.97), Death in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration.Meta -Analysis of mortality in trials of random assignment of remdesivir or control to hospitalized patients with Covid -19 with <7 days of symptoms + one risk factor for progression. Randomized remdesivir IV 200 mg on Day 1, then 100 mg x 2 days or placebo. Excluded if needing oxygen, previous COVID -19 hospitalization, treated for COVID -19 or vaccinated. Primary endpoint: Covid -19 related hospitalization or death from any cause by Day 28. A secondary end point: Covid -19-related medically attended visits. The safety endpoint: any adverse event. 562 patients: 279 remdesivir , 283 placebo Results: 87% lower risk of hospitalization or death with remdesivir vs. placebo Cost $2,000/course Gottlieb R, et al. Early remdesivir to prevent progression to severe Covid -19 in outpatients. N Engl J Med 2022; 386:305 -315. Case 1 MR is a 56 yoman presenting to walk -in clinic with 3 -day history of worsening congestion, persistent cough, and headache. His wife tested positive for COVID 5 days ago. Pt has Type 2 diabetes, hypertension, hyperlipidemia and obesity (BMI 31.2). A rapid test is positive for SARS CoV-2. Pt is unvaccinated with no history prior COVID infection. VS: Temp 100.5, RR 24, HR 90, BP 140/72, O2 room 30 units QHS, mg 100 mg 10 mg qpm, and aspirin 81 mg QD Which outpatient treatment option would you recommend? What if his eGFR was 20 ml/min? What if his oxygen saturations were 87% on Molnupiravir Oral virus mutagenesis Broad spectrum: influenza, SARS CoV -2, & MERS Increases G to A and C to U transition mutations in replicating coronaviruses Results in fatal errors in replication, reducing viral production High genetic barrier to resistance EUA indication: In ambulatory patients (18 years) with mild to moderate COVID -19 at high risk for progression to severe disease who have no other treatment options (not accessible or clinically appropriate); WHO agrees Not authorized for: Use in patients <18 yrsold Pts hospitalized with COVID -19 If later require hospitalization, then complete 5 -day course Use longer than 5 consecutive days Pre-exposure or post -exposure prophylaxis for COVID -19Kabinger F, Stiller et al. Mechanism of Molnupiravir -Induced SARS -CoV-2 mutagenesis. Natural Structural at https://www.biorxiv.org/content/10.1101/2021.05.11.443555v1.full , accessed 12/15/21. Molnupiravir for oral treatment of COVID -19 in non-hospitalized patients: MOVe -OUT Study Phase 3, double -blind, randomized, placebo -controlled trial Evaluate safety and efficacy of molnupiravir Conducted in 107 sites in 20 countries Non-hospitalized, unvaccinated adults with mild to moderate COVID -19, PCR test confirmed with at least one risk factor to develop severe illness Age >60 year Active cancer Chronic kidney disease COPD Obesity (BMI >30) HF/CAD/CM Diabetes Exclusion Need hospitalization within 48 hrs Pregnancy Renal: dialysis or eGFR <30 ml/min Platelet <100,000 Covid vaccination Primary end point: incidence hospitalization or death at day 29MOVe -OUT Study Results Used a modified intent -to-treat analysis (at least one dose) Interim analysis of 775 participants at half -way point Risk of hospitalization/death was 7.3% molnupiravir groups P=0.001, of all 1433 participants: 716 molnupiravir vs 717 placebo Baseline characteristics similar but more women received molnupiravir Outcomes with MOV not better compared to placebo if previous SARS Cov -2 infection, low baseline viral load, or pts with diabetes Adjusted RRR for all pts was 30% (95% Risk Difference % (95% CI) All-cause hospitalization >24 hrs 800 mg (four 200 mg caps) q12hrs x 5 days, with or without food Best within 72 hrsof symptom onset, ok within 5 days. No dosage adjustments for renal or hepatic function If child -bearing potential, use contraception: women (9 days), men (5d + 3 months) Not recommend: <18 year old: may affect bone & cartilage growth Pregnancy or breast -feeding (4 days after final dose) Informed consent if use while pregnant: Counsel patient risks vs benefits & document consent Advise enrollment in pregnancy surveillance program If agree, provider submits ptname & contact info to Merck 1 -877-888-4231 or https://pregnancyreporting.msd.com No drug interactions known Molnupiravir: ADRs & Safety MOVe -OUT any adverse events: 30.4% molnupiravir vs 33% placebo groups no thrombocytopenia or other lab abnormalities. Long -term safety needs studied MOVe -OUT trial plans follow -up at 7 months Risk of teratogenesis ? Oncogenesis ? Cytotoxicity?ADRs attributed to study drug Molnupiravir N=710 %Placebo N=701 % Diarrhea 2.3 3 Nausea 1 1 Bacterial pneumonia 2 1.6 Dizziness 1 1Bebtelovimab 2/11/22 FDA EUA mAB for outpatient treatment of COVID in adults or pediatric patients ( >12 yrs+ >40 kg) with high risk for progression if other treatment options not accessible or clinically appropriate. Active against Omicron VOC, give within 7 days of symptom onset Phase 2, randomized, single -dose trialevaluating the efficacy of bebtelovimab alone and bebtelovimab combined with other mAB for treating mild to moderate COVID -19 Lower rates of COVID -19 related hospitalization and death through Day 29 in treatment vs placebo 175 mg IV injection x 1, flush line with NS, and observe 1 hour No significant drug interactions Side effects <1%: itching, rash, infusion -related reactions, nausea & vomitingCase 2 AC is a 46 yowoman who presents to the ER with 5 -day history of headache, congestion, and nausea. Rapid COVID test comes back positive. She has a 10 -year history of rheumatoid arthritis, hypothyroidism and hyperlipidemia. BMI 36. AC is up to date on her COVID vaccine (2 Moderna + 3rddose 3 months ago). VS: Temp 99.1, RR 22, HR 85, BP 127/62, O2 sats 95% on tabs, 7 tabs qwk, Prednisone 20 QD, Folic Acid 1 mg QD, MVI 1 QD. What Tier does she fit under for outpatient COVID -19 treatment? Which option would you recommend? What preventative option would she have qualified to receive BEFORE she developed COVID -19 infection?ADR Reporting for EUA Drugs The prescribing healthcare provider and/or the provider's designee is/are responsible for mandatory reporting of all medication errors and serious adverse events potentially related to EUA meds within 7 days. Report includes unique identifiers \"XX use for COVID -19 under Emergency Use Authorization (EUA)\" Submit using Form 3500, to FDA MedWatch : Online www.fda.gov/medwatch/report.htm Adverse Events defined as: death; a life -threatening adverse event; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect; medical or surgical intervention to prevent death, life -threatening event, hospitalization, disability, or congenital anomaly. Resources NIH COVID -19 Treatment guidelines CDC website CDC COCA calls IDSA COVID -19 guidelines IDSA COVID Real Time Learning Network UpToDate free "}